Bristol-Myers Squibb Company ($BMY) Stock Forecast: Up 3.2% Today

What is Bristol-Myers Squibb Company?

Bristol Myers Squibb (BMY) is a pharmaceutical company known for its diverse portfolio of medications, including top-selling products like Eliquis and Opdivo. The company has been focusing on new growth drivers to offset declines in legacy product sales and maintain its competitive edge in the market.

Why is Bristol-Myers Squibb Company going up?

BMY stock is up 3.2% on Feb 5, 2026 18:22

• Despite disappointments with Eliquis and Cobenfy, Bristol Myers Squibb's strong fourth-quarter earnings report and revenue beat have propelled its stock to a bullish movement.
• The company's focus on its Growth Portfolio, featuring drugs like Opdivo and Reblozyl, has driven significant revenue growth and instilled confidence in investors.
• Bristol Myers Squibb's strategic approach to leaning on new products and potential M&A opportunities to expand its therapeutic areas has resonated well with the market, leading to the positive market movement.
• The company's ability to exceed analyst expectations and provide an optimistic outlook for future revenues has further fueled investor excitement and contributed to the bullish trend in its stock price.

BMY Price Chart

BMY Technical Analysis

BMY News

BMS Beats Again Despite Eliquis and Cobenfy Disappointments

Bristol Myers Squibb reported better-than-expected fourth-quarter earnings for 2025, with sales reaching $12.5 billion. However, its top-selling blood thinner Eliquis missed analyst expectations, despite projections for 10-15% growth in 2026, followed by a significant decline in 2027 due to European exclusivity loss. Additionally, sales of the schizophrenia drug Cobenfy remained sluggish, though BMS is planning further studies to boost its uptake.

https://www.biospace.com/business/bms-beats-again-despite-eliquis-and-cobenfy-disappointments

With declining sales of legacy meds, BMS leans on new growth drivers to weather the storm

Bristol Myers Squibb (BMS) is focusing on its growth portfolio, including new products like Opdualag, Breyanzi, Camzyos, and Reblozyl, to offset expected declines in its legacy product sales. While older medications like Eliquis face patent expirations and anticipated "rapid and steep declines" in coming years, the company's new drugs contributed significantly to 2025 revenues. BMS also expresses confidence in the long-term potential of its newly launched schizophrenia drug, Cobenfy, despite its slow start, and is considering M&A opportunities to expand in existing therapeutic areas.

https://www.fiercepharma.com/pharma/stagnating-sales-older-legacy-meds-bms-leans-new-growth-drivers-weather-storm

Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates

Bristol-Myers Squibb (BMY) reported better-than-expected Q4 2025 earnings and revenues, with adjusted EPS of $1.26 surpassing the Zacks Consensus Estimate of $1.15, and total revenues of $12.5 billion exceeding estimates. The company's Growth Portfolio, including drugs like Opdivo and Reblozyl, drove a 16% year-over-year revenue increase in this segment, though its Legacy Portfolio saw a 15% decline due to generic competition. BMY also provided a positive 2026 revenue guidance, projecting $46-$47.5 billion, and announced key pipeline updates, including FDA and EU approvals for Breyanzi and a priority review for Opdivo.

https://finance.yahoo.com/news/bristol-myers-stock-q4-earnings-154900704.html

Bristol Myers Stock Rises. Why Fourth-Quarter Earnings Are Exciting Investors.

Bristol Myers Squibb's stock rose following a fourth-quarter earnings report that surpassed analyst expectations. The drugmaker also provided an optimistic outlook, further exciting investors. The company's revenue and earnings both beat forecasts for the quarter.

https://www.barrons.com/articles/bristol-myers-earnings-stock-price-8a5e147c?gaa_at=eafs&gaa_n=AWEtsqdp3ALzzSlMDkh5DLK1hkDC6JcszOywDF0WYJ8a25K7cC_PUeiR805Q&gaa_ts=6984aba1&gaa_sig=JOf93aui2prUzR7YISBAJiR1HTvFCByiV_uofT-8BsKZw8Ke2bM70DywRQTJSsyH4abK7Dv6YyN7l4rRVpUfxg%3D%3D

Bristol Myers stock rises. Why fourth-quarter earnings are exciting investors.

This article indicates that Bristol Myers stock is on the rise. This increase in stock value is attributed to the company's strong fourth-quarter earnings report, which has generated excitement among investors.

https://www.msn.com/en-us/money/topstocks/bristol-myers-stock-rises-why-fourth-quarter-earnings-are-exciting-investors/ar-AA1VJoRx?ocid=finance-verthp-feeds

Trending Today

Wingstop Inc. ($WING) Stock Forecast: Down 5.5% Today

Moderna Inc. ($MRNA) Stock Forecast: Down 6.2% Today

Freeport-McMoRan Inc. ($FCX) Stock Forecast: Down 5.2% Today

Amazon.com Inc. ($AMZN) Stock Forecast: Down 5.1% Today

Blink Charging Co. ($BLNK) Stock Forecast: Down 5.7% Today

Novavax Inc. ($NVAX) Stock Forecast: Down 5.1% Today

MGM Resorts International ($MGM) Stock Forecast: Down 5.0% Today

Rockwell Automation Inc. ($ROK) Stock Forecast: Down 5.3% Today

C3.ai Inc. ($AI) Stock Forecast: Down 5.5% Today

BlackLine, Inc. ($BL) Stock Forecast: Down 5.3% Today

Bristol-Myers Squibb Company Price History

01.09.2025 - BMY Stock was up 5.5%

• The bullish movement in BMY could be attributed to investors favoring its growth potential despite facing generic headwinds.
• The comparison with Merck (MRK) might have highlighted BMY's resilience and potential for future success, leading to increased investor confidence.
• The market's positive response indicates that BMY's strategic initiatives and focus on new treatments are resonating well with investors, driving the stock price higher.

03.11.2025 - BMY Stock was up 5.5%

• Bristol Myers Squibb's stock surged by approximately 6% after announcing a delay in the readout of a crucial Phase 3 clinical trial for its drug Cobenfy, designed for Alzheimer's disease psychosis. The market reacted positively to this unexpected news, indicating investor optimism about the drug's potential success.
• The decision to enroll more patients in the clinical trial demonstrates the company's commitment to ensuring data integrity and addressing unmet medical needs in Alzheimer's disease, further boosting investor confidence in Bristol Myers Squibb.
• Additionally, the successful achievement of a drug discovery milestone in collaboration with Terray Therapeutics showcases Bristol Myers Squibb's dedication to leveraging innovative technologies like AI to accelerate drug discovery processes, potentially leading to the development of novel and effective treatments.
• The continuation of the ADEPT-2 Phase 3 study in psychosis associated with Alzheimer's Disease, despite site irregularities, underlines Bristol Myers Squibb's adherence to rigorous clinical standards and its proactive approach to resolving challenges in clinical trials, reinforcing investor trust in the company's research and development efforts.

03.11.2025 - BMY Stock was up 5.1%

• BMY's stock surged after a positive update on its late-stage clinical trial for treating psychosis associated with Alzheimer’s disease, signaling progress in its research endeavors.
• A collaboration milestone with Terray Therapeutics highlights BMY's utilization of AI-enabled drug discovery technologies to accelerate small molecule drug development, potentially enhancing investor confidence.
• Despite delays in the Adept-2 study for Cobenfy in Alzheimer's psychosis, efforts to rectify site irregularities and continue enrolling new patients demonstrate BMY's commitment to upholding clinical standards and addressing medical needs, possibly contributing to the stock's bullish performance.

05.00.2026 - BMY Stock was down 1.7%

• Increased investments by Railway Pension Investments Ltd and CWA Asset Management Group LLC in Bristol Myers Squibb (BMY) may have hinted at uncertainties about the company's future performance, influencing the bearish trajectory.
• While Bristol Myers Squibb exceeded Q3 earnings and revenue projections and raised its dividend, market sentiments may have been dampened by apprehensions regarding the company's growth outlook.
• Favorable results from Zenas BioPharma's Phase 3 trial and the thriving Hair Loss Treatment Market could have drawn investor attention away from Bristol Myers Squibb, impacting its stock trajectory.
• The optimistic forecast for the pharmaceutical sector, evidenced by growth prospects in the aminoglycosides market, might have steered investor focus elsewhere from Bristol Myers Squibb, contributing to the downward movement in its stock.

05.01.2026 - BMY Stock was up 3.2%

• Despite disappointments with Eliquis and Cobenfy, Bristol Myers Squibb's strong fourth-quarter earnings report and revenue beat have propelled its stock to a bullish movement.
• The company's focus on its Growth Portfolio, featuring drugs like Opdivo and Reblozyl, has driven significant revenue growth and instilled confidence in investors.
• Bristol Myers Squibb's strategic approach to leaning on new products and potential M&A opportunities to expand its therapeutic areas has resonated well with the market, leading to the positive market movement.
• The company's ability to exceed analyst expectations and provide an optimistic outlook for future revenues has further fueled investor excitement and contributed to the bullish trend in its stock price.

14.10.2025 - BMY Stock was down 5.5%

• Despite strong performance in the third quarter, Bristol Myers Squibb experienced a bearish movement, possibly due to profit-taking by investors after a recent 7.2% increase in share price.
• Jim Cramer's decision to back off on Bristol-Myers might have influenced investor sentiment, leading to a sell-off in the stock.
• The market may be shifting focus towards other promising opportunities like Baidu and Alibaba, as mentioned by Jim Cramer, diverting attention away from Bristol-Myers Squibb in the short term.

30.09.2025 - BMY Stock was up 5.0%

• Investors are optimistic about BMY's upcoming Q3 earnings, expecting a boost from the rising demand for new therapies like Opdivo and Camzyos.
• The market movement reflects confidence in BMY's ability to navigate through declines in legacy-drug sales by focusing on its newer, more promising treatments.
• The bullish trend suggests that investors may be considering buying or holding BMY stock in anticipation of positive earnings results driven by the success of its innovative therapies.

30.09.2025 - BMY Stock was up 5.0%

• BMY saw a positive uptrend after surpassing Q3 earnings and sales expectations, boosted by the success of key drugs including Opdivo, Reblozyl, and Breyanzi.
• The decision to increase its 2025 sales forecast despite decreases in older drugs demonstrates confidence in its newer treatments and overall growth strategy.
• Market sentiment is favorable towards BMY's performance, especially as the growing demand for cutting-edge medications like Opdivo and Camzyos offsets declines in older products.

03.09.2025 - BMY Stock was down 5.0%

• BMY stock price dropped by 3.58% in the current session, continuing its downward trend over the past month and year.
• The Price Over Earnings overview indicates a decline in the stock's performance, possibly raising concerns among long-term shareholders.
• The bearish movement could be attributed to various factors such as disappointing earnings reports, regulatory setbacks, or broader market conditions impacting the pharmaceutical sector.

06.00.2026 - BMY Stock was up 5.1%

• A recent collaboration between Gilead and OncoNano Medicine utilizing OncoNano's drug delivery platform may have attracted investor interest in the pharmaceutical sector, benefiting companies like Bristol Myers Squibb.
• Robeco Institutional Asset Management B.V. raised its stake in BMY by 6.4% during the 3rd quarter, indicating a growing confidence in the company's future prospects, potentially influencing the bullish movement.
• Despite some reduction in BMY position by D.A. Davidson & CO., the overall positive sentiment towards the company, especially post exceeding earnings estimates and offering strong guidance, likely overshadowed this sell-off.
• The comparison between Zenas Biopharma's obexelimab and Amgen's Uplizna in the Phase 3 trial may have highlighted Bristol Myers Squibb's competitive edge or potential in the pharmaceutical market, fueling investor optimism and driving the stock price upwards.

31.06.2025 - BMY Stock was down 5.4%

• BMY posted robust Q2 earnings and sales figures, surpassing expectations – typically prompting a bullish market response. However, missing EPS estimates and reducing the 2025 EPS guidance likely led to the bearish outlook.
• Uncertainty surrounding the company's future earnings potential may have triggered the negative market reaction, despite a positive sales forecast.
• Investors could be exercising caution due to conflicting analyst recommendations, with some advising to adopt a wait-and-see strategy before the Q2 results.
• The bearish movement in BMY's stock today might have been influenced by the overall market sentiment towards pharmaceutical stocks and broader economic conditions.

05.01.2026 - BMY Stock was up 5.7%

• Bristol Myers Squibb's stock surged due to its fourth-quarter earnings surpassing analyst expectations, showcasing a strong financial performance.
• Investor excitement was further boosted by the positive outlook provided by the company, reflecting confidence in its future growth prospects.
• Revenue growth, particularly driven by successful immuno-oncology treatments, helped offset the decline in sales of older drugs, contributing to overall positive market sentiment.
• The impressive performance in Q4 2025 and the promising outlook for 2026 underscored Bristol Myers Squibb's resilience in adapting to market changes and solidifying its position in the pharmaceutical industry.